You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve

 

Online download statistics by month:

Online download statistics by month: February 2021 to July 2025

AbstractFullPdf
Feb 2021451451250
Mar 2021321321117
Apr 202111511553
May 202115615659
Jun 202115515542
Jul 202113413458
Aug 202115715752
Sep 202110410454
Oct 2021989845
Nov 2021979343
Dec 2021797918
Jan 2022727967
Feb 2022737548
Mar 202211512446
Apr 2022879730
May 2022889046
Jun 2022727338
Jul 2022747723
Aug 2022727418
Sep 2022777957
Oct 2022697149
Nov 2022959631
Dec 2022677126
Jan 2023777829
Feb 20239910023
Mar 2023788126
Apr 2023565936
May 2023717121
Jun 2023545516
Jul 2023656522
Aug 2023343514
Sep 2023353616
Oct 2023525328
Nov 2023808222
Dec 202312212218
Jan 2024484918
Feb 2024666733
Mar 2024444436
Apr 2024363622
May 2024404221
Jun 2024636232
Jul 2024788051
Aug 2024403920
Sep 2024454789
Oct 2024383830
Nov 2024495118
Dec 202414014739
Jan 2025585819
Feb 202518018040
Mar 2025838330
Apr 2025808149
May 202517317627
Jun 2025606140
Jul 2025110
Total497350482155